← العودة إلى الصفحة الرئيسية
آسيا · الأسواق الإقليمية · CNBC-TV18

Glenmark shares rise after US arm launches cancer therapy drug

نشره CNBC-TV18 · الهند منذ 58 د
Glenmark shares rise after US arm launches cancer therapy drug - CNBC TV18
Glenmark shares rise after US arm launches cancer therapy drug - CNBC TV18 · CNBC-TV18

ملخص مفصل

INLYTA is used in Kidney Cancer (Renal Cell Carcinoma) treatment. It is used as a standalone treatment when prior systemic therapy has been unsuccessful, or as a first-line treatment for advanced disease in combination with immunotherapy agents such as pembrolizumab or avelumab.

Glenmark Pharma shares gained up to 2% on Monday, November 16, after the company announced that its US arm has launched the generic version of INLYTA® (Axitinib) Tablets after regulatory approval.

In an exchange filing issued today, the company said that Glenmark Pharmaceuticals Inc., USA, the Mumbai-based pharma company's American arm, launched Axitinib Tablets, 1 mg and 5 mg.

This product is an authorised generic version of INLYTA®1 (axitinib) tablets, which was originally developed by Pfizer. This drug is used as a Cancer therapy treatment

INLYTA is used in Kidney Cancer (Renal Cell Carcinoma) treatment. It is used as a standalone treatment when prior systemic therapy has been unsuccessful, or as a first-line treatment for advanced disease in combination with immunotherapy agents such as pembrolizumab or avelumab.

When we gauge the commercial potential of this drug, as per the North Carolina-based IQVIA® sales data for the 12 months ending September 2026, US annual sales of INLYTA® Tablets were approximately $538.4 million.

Marc Kikuchi, President & Business Head, North America, said, “The launch of Axitinib Tablets reinforces Glenmark’s commitment to expanding access to quality, affordable medicines for patients in the United States. By adding this important product to our portfolio, we continue to strengthen our focus on addressing the evolving needs of patients and healthcare providers.”

When we take a quick look at the company's quarterly performance, the company reported its quarterly results on November 5. In the September-ended quarter, the company recorded a net profit drop of 56.7% year on year to ₹264 crore, compared with ₹610 crore last year.

Revenue fell 29.8% to ₹4,247.3 crore from ₹6,046.8 crore a year earlier. Earnings before interest, tax, depreciation and amortisation (EBITDA) declined 63.4% to ₹864 crore from ₹2,360 crore, while the EBITDA margin narrowed to 20% from 39% in Q2 FY26.

The shares started the day on a positive note.

مطلع المقال، مقتطف من CNBC-TV18. لقراءة المقال كاملًا، افتحه على موقع الناشر.

اقرأ المقال كاملًا على CNBC-TV18 سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.cnbctv18.com)

يستحق القراءة أيضًا